{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-036859","form_type":"8-K","ticker":"OVID","cik":"0001636651","company_name":"Ovid Therapeutics Inc.","filed_at":"2024-08-13T23:59:59+00:00","discovered_at":"2026-05-14T18:03:13.900640+00:00","generated_at":"2026-05-31T09:44:00.917958+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Ovid Therapeutics cuts workforce 43%, suspends OV329 IV, reports Q2 net income of $8.5M on $77M cash","bullets":["Reduced headcount by 17 employees (43%) to prioritize core programs; expects $3.4M cash restructuring costs through mid-2025.","Suspended OV329 IV program for refractory status epilepticus; oral OV329 Phase 1 MAD results due H2 2024.","Appointed Dr. Amanda Banks as Chief Development Officer in July 2024.","Q2 2024 net income of $8.5M ($0.12 EPS) vs net loss of $12.4M ($0.18 loss) in 2023, aided by $29M fair value gain on royalty liability.","Cash and marketable securities of $77.0M expected to fund operations and 5 clinical/regulatory milestones through late H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-036859","json":"https://secwatch.observer/filing/0001628280-24-036859.json","markdown":"https://secwatch.observer/filing/0001628280-24-036859.md","text":"https://secwatch.observer/filing/0001628280-24-036859.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1636651/000162828024036859/0001628280-24-036859-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1636651/000162828024036859/ovid-20240813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:44:00.917958+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}